SEC Form 4
Boston Scientific Corp. (BSX) insider trading
In the 12 months to Oct 24, 2026, 4 BSX insiders reported open-market sales of $24.3M across 5 filings; 5 insiders bought $10.0M.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $24.3M
- 5 filings · 4 insiders
- Open-market purchases
- $10.0M
- 8 filings
- Pre-arranged sales (10b5-1)
- 5 of 5
- All $24.3M sold was pre-arranged
Who traded BSX, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
BSX daily close from Oct 24, 2025 to Oct 23, 2026, between $41.58 and $104.98, last $45.69. 5 sale and 8 purchase filings by 8 insiders, marked at their filing dates. Michael F. Mahoney, Chairman, President & CEO: sold $15.0M and bought $9.0M across 2 filings, first filed Feb 3, 2026, last Aug 5, 2026. Joseph Michael Fitzgerald, EVP & Group Pres, Cardiology: sold $5.0M across 1 filing, first filed Nov 4, 2025, last Nov 4, 2025. Ellen M. Zane, Director: sold $2.6M across 2 filings, first filed Oct 28, 2025, last Nov 6, 2025. Arthur C. Butcher, EVP& Grp Pres, MedSurg & APAC: sold $1.8M across 1 filing, first filed Dec 2, 2025, last Dec 2, 2025. Edward J. Ludwig, Director: bought $430.3K across 2 filings, first filed May 21, 2026, last Aug 3, 2026. David C. Habiger, Director: bought $407.9K across 3 filings, first filed May 21, 2026, last Aug 7, 2026. Susan E. Morano, Director: bought $100.4K across 1 filing, first filed Aug 26, 2026, last Aug 26, 2026. Cheryl Pegus, Director: bought $100.0K across 1 filing, first filed May 21, 2026, last May 21, 2026.
Largest mark · tap a row for others
Michael F. Mahoney · Chairman, President & CEO
Sale $15,043,394
160,901 shares at $93.49 avg
Filed Feb 3, 2026 · traded Feb 2
Pre-arranged (10b5-1) · close on filing date $91.62
Michael F. Mahoney · Chairman, President & CEO
Chairman, President & CEO
$15.0M sold$9.0M boughtJoseph Michael Fitzgerald · EVP & Group Pres, Cardiology
EVP & Group Pres, Cardiology
$5.0M soldEllen M. Zane · Director
Director
$2.6M soldArthur C. Butcher · EVP& Grp Pres, MedSurg & APAC
EVP& Grp Pres, MedSurg & APAC
$1.8M soldEdward J. Ludwig · Director
Director
$430.3K boughtDavid C. Habiger · Director
Director
$407.9K boughtSusan E. Morano · Director
Director
$100.4K boughtCheryl Pegus · Director
Director
$100.0K boughtHas Boston Scientific Corp.'s CEO sold stock?
Yes. Michael F. Mahoney (CEO) sold 160,901 shares ($15.0M) in Feb 2026, all under a pre-arranged 10b5-1 plan.
Open-market trades
13 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Michael F. Mahoney | Chairman, President & CEO | $15.0M | $9.0M | 2 | 100% of sales | |
| Joseph Michael Fitzgerald | EVP & Group Pres, Cardiology | $5.0M | — | 1 | 100% of sales | |
| Ellen M. Zane | Director | $2.6M | — | 2 | 100% of sales | |
| Arthur C. Butcher | EVP& Grp Pres, MedSurg & APAC | $1.8M | — | 1 | 100% of sales | |
| Edward J. Ludwig | Director | — | $430.3K | 2 | — | |
| David C. Habiger | Director | — | $407.9K | 3 | — | |
| Susan E. Morano | Director | — | $100.4K | 1 | — | |
| Cheryl Pegus | Director | — | $100.0K | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Susan E. Morano Director | Purchase | 2,040 | $49.22 | $100.4K | 13,784 | |
traded | David C. Habiger Director | Purchase | 2,100 | $47.59 | $99.9K | 17,160 | |
traded | Michael F. Mahoney Chairman, President & CEO | Purchase | 186,240 | $48.33 | $9.0M | 1,590,024 | |
traded | David C. Habiger Director | Purchase | 1,182 | $48.13 | $56.9K | 15,060 | |
traded | Edward J. Ludwig Director | Purchase | 5,000 | $45.48 | $227.4K | 30,359 | |
traded | David C. Habiger Director | Purchase | 4,450 | $56.43 | $251.1K | 13,878 | |
traded | Edward J. Ludwig Director | Purchase | 3,580 | $56.68 | $202.9K | 25,359 | |
traded | Cheryl Pegus Director | Purchase | 1,770 | $56.49 | $100.0K | 1,770 | |
traded | Michael F. Mahoney Chairman, President & CEO | SalePre-arranged (10b5-1) | 160,901 | $93.49 | $15.0M | 1,411,735 | |
traded | Arthur C. Butcher EVP& Grp Pres, MedSurg & APAC | SalePre-arranged (10b5-1) | 17,313 | $101.55 | $1.8M | 23,600 | |
traded | Ellen M. Zane Director | SalePre-arranged (10b5-1) | 12,891 | $98.28 | $1.3M | 24,134 | |
traded | Joseph Michael Fitzgerald EVP & Group Pres, Cardiology | SalePre-arranged (10b5-1) | 50,000 | $99.47 | $5.0M | 224,742 | |
traded | Ellen M. Zane Director | SalePre-arranged (10b5-1) | 12,891 | $101.38 | $1.3M | 24,134 |
GET /stocks/filings/vX/form-4?tickers=BSX&filing_date.gte=2025-10-24&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"BSX",
"BSXw"
],
"issuer_cik": "0000885725",
"owner_cik": "0001983791",
"accession_number": "0001225208-26-007337",
"form_type": "4",
"filing_date": "2026-08-26",
"period_of_report": "2026-08-25",
"issuer_name": "BOSTON SCIENTIFIC CORP",
"issuer_trading_symbol": "BSX",
"owner_name": "Morano Susan E",
"is_director": true,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-08-25",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 2040,
"transaction_price_per_share": 49.2195,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 13784,
"transaction_value": 100407.78,
"direct_or_indirect": "D"
},
{
"tickers": [
"BSX",
"BSXw"
],
"issuer_cik": "0000885725",
"owner_cik": "0001326409",
"accession_number": "0001225208-26-007031",
"form_type": "4",
"filing_date": "2026-08-07",
"period_of_report": "2026-08-05",
"issuer_name": "BOSTON SCIENTIFIC CORP",
"issuer_trading_symbol": "BSX",
"owner_name": "Habiger David C",
"is_director": true,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-08-05",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 2100,
"transaction_price_per_share": 47.589,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 17160,
"transaction_value": 99936.9,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $47.21 to $47.98, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 114 records
- Option exercises44 records
- Tax withholding37 records
- Grants and awards20 records
- Gifts7 records
- Other6 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
Build this yourself
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for BSX every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.